Compare
Aardvark Therapeutics, Inc. vs Bristol Myers Squibb Co vs TherapeuticsMD, Inc. vs Eli Lilly & Co
| Latest fiscal year | Aardvark Therapeutics, Inc. AARD | Bristol Myers Squibb Co BMY | TherapeuticsMD, Inc. TXMD | Eli Lilly & Co LLY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $0 | $48.19B | $3.02M | $65.18B |
| Revenue growth (YoY) | n/a | -0.2% | +71.6% | +44.7% |
| Gross margin | n/a | n/a | n/a | 83.0% (computed) |
| Operating margin | n/a | n/a | -145.3% | n/a |
| Net margin | n/a | 14.6% | -18.8% | 31.7% |
| Net income | -$57.59M | $7.05B | -$569.0K | $20.64B |
| EPS (Diluted) | -$2.93 | $3.46 | -$0.05 | $22.95 |
| Operating cash flow | -$54.17M | $14.16B | $2.45M | $16.81B |
| Free cash flow | -$54.27M | $12.85B | n/a | n/a |
| Cash & equivalents | $47.05M | $10.21B | n/a | $7.27B |
| Total assets | $117.18M | $90.04B | $37.66M | $112.48B |
| Total liabilities | $10.55M | $71.53B | $10.78M | n/a |
| Shareholders' equity | $106.63M | $18.47B | $26.88M | $26.54B |
| Return on year-end equity | -54.0% | 38.2% | -2.1% | 77.8% |
| Shares outstanding | 21.82M | n/a | 11.57M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Aardvark Therapeutics, Inc. | Bristol Myers Squibb Co | TherapeuticsMD, Inc. | Eli Lilly & Co |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $48.19B Ended 2025-12-31 | $3.02M Ended 2025-12-31 | $65.18B Ended 2025-12-31 |
| 1 year earlier | n/a | $48.30B Ended 2024-12-31 | $1.76M Ended 2024-12-31 | $45.04B Ended 2024-12-31 |
| 2 years earlier | n/a | $45.01B Ended 2023-12-31 | $1.30M Ended 2023-12-31 | $34.12B Ended 2023-12-31 |
| 3 years earlier | n/a | $46.16B Ended 2022-12-31 | $69.96M Ended 2022-12-31 | $28.54B Ended 2022-12-31 |
| 4 years earlier | n/a | $46.38B Ended 2021-12-31 | $2.57M Ended 2021-12-31 | $28.32B Ended 2021-12-31 |